The detection of KRAS mutations in tumor tissue is a well-known predictor of resistance to the treatment of anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC) [1]. The gene discussed is EGFR; the disease is neoplasm.